Yuhan Corporation announced that the company will receive $65 million in milestone payment from Janssen Biotech for Lazertinib, a third-generation EGFR TKI for NSCLC (non-small cell lung cancer), which was out-licensed to Janssen in 2018. As a result, Yuhan became the first in the Korean pharmaceutical industry to earn $100 million in milestone payments from an out-licensing deal.
This milestone is for the initiation of phase 3 clinical trial of the combined use of Yuhan’s Lazertinib and Janssen’s Amivantamab as the first-line treatment for EGFR mutant NSCLC.
Moreover, Yuhan is independently conducting a multinational phase 3 clinical trial as well to confirm the efficacy and safety of Lazertinib alone as a first-line monotherapy for patients with EGFR mutation-positive NSCLC.
An official from Yuhan said, “Yuhan and Janssen are working closely together to provide better treatment options for those non-small cell lung cancer patients.”